BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Edlin BR. Hepatitis C screening: getting it right. Hepatology 2013;57:1644-50. [PMID: 23239521 DOI: 10.1002/hep.26194] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
Number Citing Articles
1 Merchant RC, Baird JR, Liu T, Taylor LE, Montague BT, Nirenberg TD. Brief intervention to increase emergency department uptake of combined rapid human immunodeficiency virus and hepatitis C screening among a drug misusing population. Acad Emerg Med 2014;21:752-67. [PMID: 25125271 DOI: 10.1111/acem.12419] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
2 Fisher DG, Hess KL, Erlyana E, Reynolds GL, Cummins CA, Alonzo TA. Comparison of Rapid Point-of-Care Tests for Detection of Antibodies to Hepatitis C Virus. Open Forum Infect Dis 2015;2:ofv101. [PMID: 26269795 DOI: 10.1093/ofid/ofv101] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
3 Singal AG, Dharia TD, Malet PF, Alqahtani S, Zhang S, Cuthbert JA. Long-term benefit of hepatitis C therapy in a safety net hospital system: a cross-sectional study with median 5-year follow-up. BMJ Open 2013;3:e003231. [PMID: 24002983 DOI: 10.1136/bmjopen-2013-003231] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
4 Carlucci JG, Farooq SA, Sizemore L, Rickles M, Cosley B, McCormack L, Wester C. Low hepatitis C antibody screening rates among an insured population of Tennessean Baby Boomers. PLoS One 2017;12:e0188624. [PMID: 29190748 DOI: 10.1371/journal.pone.0188624] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
5 de Araujo Neto JM, Coelho HSM, Chindamo MC, Rezende GFM, Nunes Pannain VL, Bottino AMCF, Bruzzi Porto LF, Luiz RR, Villela-Nogueira CA, Perez RM. Lower levels of dehydroepiandrosterone sulfate are associated with more advanced liver fibrosis in chronic hepatitis C. J Viral Hepat 2018;25:254-61. [PMID: 29091323 DOI: 10.1111/jvh.12812] [Reference Citation Analysis]
6 Edlin BR, Winkelstein ER. Can hepatitis C be eradicated in the United States? Antiviral Res. 2014;110:79-93. [PMID: 25110202 DOI: 10.1016/j.antiviral.2014.07.015] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
7 Hermetet C, Dubois F, Gaudy-Graffin C, Bacq Y, Royer B, Gaborit C, D'Alteroche L, Desenclos JC, Roingeard P, Grammatico-Guillon L. Continuum of hepatitis C care in France: A 20-year cohort study. PLoS One 2017;12:e0183232. [PMID: 28850623 DOI: 10.1371/journal.pone.0183232] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
8 Saxena V, Manos MM, Yee HS, Catalli L, Wayne E, Murphy RC, Shvachko VA, Pauly MP, Chua J, Monto A. Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis. Aliment Pharmacol Ther. 2014;39:1213-1224. [PMID: 24654657 DOI: 10.1111/apt.12718] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]